Clinigence Holdings, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Clinigence Holdings, Inc.

Clinigence Holdings, Inc. is best understood today as part of the U.S. listed healthcare-services universe, even though the company has undergone a major corporate evolution. The original Clinigence platform was associated with healthcare analytics and population health management, reflecting the shift in the American system toward value-based care, care coordination, and risk-bearing provider models. The company came to the public markets through a reverse merger in 2019; SEC history shows an Atlanta-era corporate footprint at that stage, followed by a later strategic center of gravity in Houston, Texas. After the 2022 merger with Nutex Health Holdco LLC, the combined enterprise adopted the Nutex Health Inc. name, but the Clinigence legacy remains important for understanding the company’s population-health roots. Operationally, the business is built around two complementary pillars. First is the hospital division, which focuses on micro-hospitals and other community-based care facilities, alongside specialty and emergency/inpatient services. Second is the Population Health Management (PHM) division, which is centered on primary-care-oriented risk management, physician network coordination, and technology-enabled tools to improve patient tracking and care delivery. This dual model gives the company a hybrid profile: it is both a healthcare operator and, in part, a care-management platform. That is a meaningful differentiator versus either pure-play hospital chains or pure software vendors. From a competitive standpoint, Clinigence/Nutex occupies a niche position in the U.S. healthcare market. It competes indirectly with larger hospital systems, outpatient operators, managed-care intermediaries, and population-health software providers. Its edge is primarily operational flexibility, local market penetration, and a capital structure that can support targeted expansion of smaller facilities rather than broad national hospital networks. At the same time, the company remains smaller than major U.S. peers, which means execution risk, reimbursement dynamics, and regulatory discipline remain especially important. The company’s geographic footprint is predominantly in the United States, with headquarters in Houston, Texas, and operations spread across multiple states. For French, Belgian, and Swiss investors, the key market reference is the U.S. public market; the company is associated with the NASDAQ through the NUTX listing, and the Clinigence name is best viewed as part of the corporate history rather than the current standalone commercial brand. Recent items to monitor include hospital expansion, population-health initiatives, and SEC disclosures such as Form 4 insider transactions, which can provide useful signals about insider sentiment and ownership behavior.